Life Sciences Innovative Manufacturing Fund (Rolling)

Fund details

Applicants will be prioritised based on their alignment to the fund’s objectives: 

• To increase UK health resilience by strengthening the UK’s manufacturing capacity and capability. We define health resilience as the UK’s ability to withstand and recover from health emergencies such as pandemics, long-term healthcare challenges and system shocks such as supply chain disruption. 

• To create economic opportunity through investments that will make a substantial contribution to Gross Value Added (GVA) and provide high-wage, high-skilled jobs around the UK.  

Eligibility 

To be eligible for the fund, your project must: 

• Have a total cost (capital and non-capital costs) of at least £8 million 
• Be located in the UK 

• Be primarily a capital investment 

• Be a single company investment (as opposed to forming a partnership between companies or other types of organisations) 

• Require only the amount of grant requested to proceed. For example, without the specific amount of funding you are requesting your project wouldn’t go ahead or go ahead at a smaller scale, go ahead overseas or would be significantly delayed (three years or more) 

• Be a manufacturing project for the manufacture of: 

• • Human medicines (this includes both the manufacture of active pharmaceutical ingredients (API)/drug substance and finished product/drug product). 

• • Medical diagnostics – for both disease identification and monitoring 

• • Medtech products – all types of medical devices related to human health. 

 The fund is open to applications for MHRA-licenced medicines, medical and diagnostic devices registered with the MHRA, and products in development where approval to market the device in the UK is intended to be sought for commercial scale-up, for example a manufacturing project for clinical trials or investigational studies.